A randomised, open comparative study of Dihydroartemisinin-piperaquine versus Chloroquine for the treatment of Vivax malaria

Completed

• Conditions: ncomplicated vivax malaria; Infections and Infestations; Uncomplicated vivax malaria

• Registration Number: ISRCTN87827353
• Lead Sponsor: niversity of Oxford (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-08-08
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Males and Females aged over 12 months
2. Body weight more 5 kg
3. Microscopically confirmed, mono-infection of Plasmodium vivax (parasitaemia more than or equal to 5/500 White Blood Cells [WBC])
4. Fever (axillary temperature more than or equal to 37.5°C) OR history of fever
5. Informed consent obtained by patients and in the case of children, by parents or guardians
6. Willingness and ability to comply with the study protocol

Exclusion Criteria

1. Known hypersensitivity to the study drugs
2. Presence of intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study
3. Pregnancy or lactation, urine test for beta human Chorionic Gonadotropin (beta-hCG) to be performed on any woman of child bearing age
4. Mefloquine treatment in the previous 60 days
5. Dapsone Pyrimethamine (DP) treatment in the previous three months

Study & Design

• Study Type: Interventional
• Study Design: Not specified